Beruflicher Werdegang

1996–2002 Studium der Humanmedizin, Universität Würzburg, Abschluss Staatsexamen
2003–2004 Arzt im Praktikum, Institut für Pathologie, Universitätsklinikum Würzburg
2005–2013 Assistenzarzt, Pathologisches Institut, Universitätsklinikum Tübingen
2013–2021 Facharzt für Pathologie, Pathologisches Institut, Universitätsklinikum Tübingen
2015–2021 Arzt im MVZ, Universitätsklinikum Tübingen
2018–2021 Oberarzt, Universitätsklinikum Tübingen:
▸Ärztliche Leitung Aussen-/Schnellschnittlabor CRONA-Klinikum
▸Ärztliche Leitung CCC-Tumorbank
▸Lehrbeauftragter des Pathologischen Instituts

  Spezielle Interessengebiete

- Uropathologie
- Gastrointestinale Pathologie
- Molekulare Pathologie

  Promotion

Promotion Charité Universitätsklinikum Berlin (2012)
bei Herrn Prof. Köhrle, Institut für Experimentelle Endokrinologie der Medizinischen Fakultät:

  Publikationen

  • Scharpf M, Schweizer U, Arzberger T, Roggendorf W, Schomburg L, Köhrle J.
    Neuronal and ependymal expression of selenoprotein P in the human brain,J Neural Transm (Vienna) 2007 , PMID: 17245539.
  • Renko K, Werner M, Renner-Müller I, Cooper TG, Yeung CH, Hollenbach B, Scharpf M, Köhrle J, Schomburg L, Schweizer U.
    Hepatic selenoprotein P (SePP) expression restores selenium transport and prevents infertility and motor-incoordination in Sepp-knockout mice,Biochem J 2008 , PMID: 17961124.
  • Rempp H, Scharpf M, Voigtlaender M, Schraml C, Schmidt D, Fend F, Claussen CD, Enderle MD, Pereira PL, Clasen S.
    Sustained growth of the ex vivo ablation zones' critical short axis using gas-cooled radiofrequency applicators,Cardiovasc Intervent Radiol 2011 , PMID: 20661567.
  • Kraemer B, Rothmund R, Fischer K, Scharpf M, Fend F, Smaxwil L, Enderle MD, Wallwiener D, Neugebauer A.
    A prospective, randomized, experimental study to investigate the peritoneal adhesion formation of noncontact argon plasma coagulation in a rat model,Fertil Steril 2011 , PMID: 21377553.
  • Mundhenk J, Hennenlotter J, Zug L, Alloussi SH, Todenhoefer T, Gakis G, Aufderklamm S, Scharpf M, Kuehs U, Stenzl A, Schwentner C.
    Evidence for PTEN-independent Akt activation and Akt-independent p27(Kip1) expression in advanced bladder cancer,Oncol Lett 2011 , PMID: 22848272.
  • Gakis G, Hennenlotter J, Scharpf M, Hevler J, Schilling D, Kuehs U, Stenzl A, Schwentner C.
    XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma,World J Urol 2011 , PMID: 21113600.
  • Heni M, Hennenlotter J, Scharpf M, Lutz SZ, Schwentner C, Todenhöfer T, Schilling D, Kühs U, Gerber V, Machicao F, Staiger H, Häring HU, Stenzl A.
    Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer,PLoS One 2012 , PMID: 23251408.
  • Schmehl J, Scharpf M, Brechtel K, Kalender G, Heller S, Claussen CD, Lescan M.
    Epithelioid angiosarcoma with metastatic disease after endovascular therapy of abdominal aortic aneurysm,Cardiovasc Intervent Radiol 2012 , PMID: 21735325.
  • Mittag F, Hennenlotter J, Minkley L, Ipach I, Schilling D, Scharpf M, Stenzl A, Leichtle U, Kluba T.
    Alteration of bone sialoprotein expression in osseous metastasized renal cell carcinomas and the tumor surrounding tissue,Clin Exp Metastasis 2012 , PMID: 22130963.
  • Rothmund R, Schaeller D, Neugebauer A A, Scharpf M M, Fend F F, Schenk M, Wallwiener D, Kraemer B.
    Evaluation of thermal damage in a pig model,J Invest Surg 2012 , PMID: 22272637.
  • Kruck S, Merseburger AS, Hennenlotter J, Scharpf M, Eyrich C, Amend B, Sievert KD, Stenzl A, Bedke J.
    High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma,BJU Int 2012 , PMID: 21981759.
  • Amend B, Hennenlotter J, Scharpf M, Kruck S, Kuehs U, Senger E, Merseburger AS, Kuczyk MA, Sievert KD, Stenzl A, Bedke J.
    Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma,World J Urol 2012 , PMID: 21822918.
  • Rothmund R, Kraemer B, Neis F, Brucker S, Wallwiener M, Reda A, Hausch A, Scharpf M, Szyrach MN.
    Efficacy and safety of the novel electrosurgical vessel sealing and cutting instrument BiCision®,Surg Endosc 2012 , PMID: 22678171.
  • Bedke J, Chun FK, Merseburger A, Scharpf M, Kasprzyk K, Schilling D, Sievert KD, Stenzl A, Kruck S.
    Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy,BJU Int 2012 , PMID: 23134582.
  • Bedke J, Chun FK, Merseburger AS, Scharpf M, Kasprzyk K, Schilling D, Sievert KD, Stenzl A, Kruck S.
    Reply: Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy,BJU Int 2013 , PMID: 23444937.
  • Kruck S, Scharpf M, Stenzl A, Bedke J.
    A rare case of synchronous renal cell carcinoma of the bladder presenting with gross hematuria,Rare Tumors 2013 , PMID: 23888219.
  • Kruck S, Eyrich C, Scharpf M, Sievert KD, Fend F, Stenzl A, Bedke J.
    Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma,Int J Mol Sci 2013 , PMID: 23708097.
  • Rempp H, Voigtländer M, Schenk M, Enderle MD, Scharpf M, Greiner TO, Neugebauer A, Hoffmann R, Claussen CD, Clasen S.
    Internally gas-cooled radiofrequency applicators as an alternative to conventional radiofrequency and microwave ablation devices: an in vivo comparison,Eur J Radiol 2013 , PMID: 23522746.
  • Fisel P, Kruck S, Winter S, Bedke J, Hennenlotter J, Nies AT, Scharpf M, Fend F, Stenzl A, Schwab M, Schaeffeler E.
    DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome,Clin Cancer Res 2013 , PMID: 23881922.
  • Petkova N, Hennenlotter J, Sobiesiak M, Todenhöfer T, Scharpf M, Stenzl A, Bühring HJ, Schwentner C.
    Surface CD24 distinguishes between low differentiated and transit-amplifying cells in the basal layer of human prostate,Prostate 2013 , PMID: 23836489.
  • Michaelis M, Gralla O, Behrends T, Scharpf M, Endermann T, Rijntjes E, Pietschmann N, Hollenbach B, Schomburg L.
    Selenoprotein P in seminal fluid is a novel biomarker of sperm quality,Biochem Biophys Res Commun 2014 , PMID: 24361887.
  • Rempp H, Mezger D, Voigtlaender M, Scharpf M, Hoffmann R, Pereira PL, Enderle MD, Claussen CD, Clasen S.
    A comparison of internally water-perfused and cryogenically cooled monopolar and bipolar radiofrequency applicators in ex vivo liver samples,Acad Radiol 2014 , PMID: 24703480.
  • Kraemer B, Rothmund R, Fischer K, Scharpf M, Smaxwil L, Enderle MD, Wallwiener C, Neugebauer A.
    A Prospective Experimental Study to Investigate the Peritoneal Adhesion Formation of Argon Plasma Coagulation (APC) Versus a Novel Aerosol Plasma in a Rat Model,Surg Innov 2014 , PMID: 24172164.
  • Kraemer B, Scharpf M, Planck C, Tsaousidis C, Enderle MD, Neugebauer A, Kroeker K, Fend F, Brucker S, Rothmund R.
    Randomized experimental study to investigate the peritoneal adhesion formation of conventional monopolar contact coagulation versus noncontact argon plasma coagulation in a rat model,Fertil Steril 2014 , PMID: 25123635.
  • Manner H, Neugebauer A, Scharpf M, Braun K, May A, Ell C, Fend F, Enderle MD.
    The tissue effect of argon-plasma coagulation with prior submucosal injection (Hybrid-APC) versus standard APC: A randomized ex-vivo study,United European Gastroenterol J 2014 , PMID: 25360316.
  • Kaufmann S, Kruck S, Kramer U, Gatidis S, Stenzl A, Roethke M, Scharpf M, Schilling D.
    Direct comparison of targeted MRI-guided biopsy with systematic transrectal ultrasound-guided biopsy in patients with previous negative prostate biopsies,Urol Int 2015 , PMID: 25227711.
  • Spether D, Scharpf M, Hennenlotter J, Schwentner C, Neugebauer A, Nüßle D, Fischer K, Zappe H, Stenzl A, Fend F, Seifert A, Enderle M.
    Real-time tissue differentiation based on optical emission spectroscopy for guided electrosurgical tumor resection,Biomed Opt Express 2015 , PMID: 25909025.
  • Karl A, Buchner A, Tympner C, Kirchner T, Ganswindt U, Belka C, Ganzer R, Burger M, Eder F, Hofstädter F, Schilling D, Sievert K, Stenzl A, Scharpf M, Fend F, Vom Dorp F, Rübben H, Schmid K, Porres-Knoblauch D, Heidenreich A, Hangarter B, Knüchel-Clarke R, Rogenhofer M, Wullich B, Hartmann A, Comploj E, Pycha A, Hanspeter E, Pehrke D, Sauter G, Graefen M, Stief C, Haese A.
    The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence,World J Urol 2015 , PMID: 25682109.
  • Gatidis S, Scharpf M, Martirosian P, Bezrukov I, Küstner T, Hennenlotter J, Kruck S, Kaufmann S, Schraml C, la Fougère C, Schwenzer NF, Schmidt H.
    Combined unsupervised-supervised classification of multiparametric PET/MRI data: application to prostate cancer,NMR Biomed 2015 , PMID: 26014883.
  • Karl A, Buchner A, Tympner C, Kirchner T, Ganswindt U, Belka C, Ganzer R, Wieland W, Eder F, Hofstädter F, Schilling D, Sievert KD, Stenzl A, Scharpf M, Fend F, Vom Dorp F, Rübben H, Schmid KW, Porres-Knoblauch D, Heidenreich A, Hangarter B, Knüchel-Clarke R, Rogenhofer M, Wullich B, Hartmann A, Comploj E, Pycha A, Hanspeter E, Pehrke D, Sauter G, Graefen M, Gratzke C, Stief C, Wiegel T, Haese A.
    Risk and timing of biochemical recurrence in pT3aN0/Nx prostate cancer with positive surgical margin - A multicenter study,Radiother Oncol 2015 , PMID: 26138059.
  • Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L.
    STAT3 regulated ARF expression suppresses prostate cancer metastasis,Nat Commun 2015 , PMID: 26198641.
  • Menegakis A, von Neubeck C, Yaromina A, Thames H, Hering S, Hennenlotter J, Scharpf M, Noell S, Krause M, Zips D, Baumann M.
    γH2AX assay in ex vivo irradiated tumour specimens: A novel method to determine tumour radiation sensitivity in patient-derived material,Radiother Oncol 2015 , PMID: 25866027.
  • Menegakis A, De Colle C, Yaromina A, Hennenlotter J, Stenzl A, Scharpf M, Fend F, Noell S, Tatagiba M, Brucker S, Wallwiener D, Boeke S, Ricardi U, Baumann M, Zips D.
    Residual γH2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness,Radiother Oncol 2015 , PMID: 26297183.
  • Fisel P, Stühler V, Bedke J, Winter S, Rausch S, Hennenlotter J, Nies AT, Stenzl A, Scharpf M, Fend F, Kruck S, Schwab M, Schaeffeler E.
    MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma,Oncotarget 2015 , PMID: 26384346.
  • Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L.
    Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis,Nat Commun 2015 , PMID: 26499136.
  • Fahmy O, Scharpf M, Fend F, Stenzl A, Gakis G.
    Feasibility of Penis-Preserving Surgery for Urethral Melanoma: Proposal for a Therapeutic Algorithm,Clin Genitourin Cancer 2015 , PMID: 26164683.
  • Fahmy O, Scharpf M, Schubert T, Feyerabend S, Stenzl A, Schwentner C, Fend F, Gakis G.
    Ten Years of Complete Remission of Pulmonary Metastasis after Post-Cystectomy Palliative Cisplatin-Gemcitabine Chemotherapy with Gefitinib for Muscle Invasive Bladder Cancer: A Case Report,Urol Int 2016 , PMID: 26863306.
  • Rothmund R, Scharpf M, Tsaousidis C, Planck C, Enderle MD, Neugebauer A, Kroeker K, Nuessle D, Fend F, Brucker S, Kraemer B.
    A Prospective Randomized Experimental Study to Investigate the Eradication Rate of Endometriosis after Surgical Resection versus Aerosol Plasma Coagulation in a Rat Model,Int J Med Sci 2016 , PMID: 26941579.
  • Rausch S, Scharpf M, Moch H, Stenzl A, Bedke J.
    [Leiomyomatous renal cell carcinoma : Controversy around a new entity],Urologe A 2016 , PMID: 26556266.
  • Bösmüller H, Klenske J, Bonzheim I, Scharpf M, Rieger N, Quintanilla-Fend L, Fend F.
    Cytokeratin-positive interstitial reticulum cell tumor: recognition of a potential ""in situ"" pattern,Hum Pathol 2016 , PMID: 26826404.
  • Agaimy A, Ben-Izhak O, Lorey T, Scharpf M, Rubin BP.
    Angiosarcoma arising in association with vascular Dacron grafts and orthopedic joint prostheses: clinicopathologic, immunohistochemical, and molecular study,Ann Diagn Pathol 2016 , PMID: 27040926.
  • Rausch S, Hennenlotter J, Scharpf M, Teepe K, Kühs U, Aufderklamm S, Bier S, Mischinger J, Gakis G, Stenzl A, Schwentner C, Todenhöfer T.
    Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma,J Cancer Res Clin Oncol 2016 , PMID: 26746655.
  • Aufderklamm S, Hennenlotter J, Todenhöfer T, Senghaas N, Scharpf M, Gakis G, Rausch S, Mischinger J, Bier S, Stenzl A, Schwentner C, Bedke J.
    Oncologic Impact of Renal Tissue Adjacent to Renal Cell Carcinoma,Anticancer Res 2016 , PMID: 27272798.
  • Winter S, Fisel P, Büttner F, Rausch S, D'Amico D, Hennenlotter J, Kruck S, Nies AT, Stenzl A, Junker K, Scharpf M, Hofmann U, van der Kuip H, Fend F, Ott G, Agaimy A, Hartmann A, Bedke J, Schwab M, Schaeffeler E.
    Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes,Sci Rep 2016 , PMID: 27435027.
  • Rausch S, Beermann J, Scharpf M, Hennenlotter J, Fend F, Stenzl A, Schollenberger D, Bedke J, Kruck S.
    Differential expression and clinical relevance of MUC1 in renal cell carcinoma metastasis,World J Urol 2016 , PMID: 26995391.
  • Neumann E, Hennenlotter J, Todenhöfer T, Scharpf M, Neumann T, Schilling D, Stenzl A, Bedke J.
    The Value and Evaluability of the PCA3 Urine Assay in Prostate Carcinoma is Independent of the Tumor Localization,Adv Ther 2017 , PMID: 28290096.
  • Kaufmann S, Mischinger J, Amend B, Rausch S, Adam M, Scharpf M, Fend F, Kramer U, Notohamiprodjo M, Nikolaou K, Stenzl A, Bedke J, Kruck S.
    First report of robot-assisted transperineal fusion versus off-target biopsy in patients undergoing repeat prostate biopsy,World J Urol 2017 , PMID: 27847972.
  • De-Colle C, Yaromina A, Hennenlotter J, Thames H, Mueller AC, Neumann T, Stenzl A, Scharpf M, Fend F, Ricardi U, Baumann M, Zips D, Menegakis A.
    Ex vivo γH2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity,Radiother Oncol 2017 , PMID: 28919005.
  • Bedke J, Heide J, Ribback S, Rausch S, de Martino M, Scharpf M, Haitel A, Zimmermann U, Pechoel M, Alkhayyat H, Shariat SF, Dombrowski F, Stenzl A, Burchardt M, Klatte T, Kroeger N.
    Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice,BJU Int 2018 , PMID: 28803448.
  • Lutz SZ, Hennenlotter J, Scharpf MO, Sailer C, Fritsche L, Schmid V, Kantartzis K, Wagner R, Lehmann R, Berti L, Peter A, Staiger H, Fritsche A, Fend F, Todenhöfer T, Stenzl A, Häring HU, Heni M.
    Androgen receptor overexpression in prostate cancer in type 2 diabetes,Mol Metab 2018 , PMID: 29249638.
  • Lutz SZ, Todenhöfer T, Wagner R, Hennenlotter J, Ferchl JM, Scharpf MO, Martus P, Staiger H, Fritsche A, Stenzl A, Häring HU, Heni M.
    Higher prevalence of lymph node metastasis in prostate cancer in patients with diabetes,Endocr Relat Cancer 2018 , PMID: 29330196.
  • Kraemer B, Scharpf M, Keckstein S, Dippon J, Tsaousidis C, Brunecker K, Enderle MD, Neugebauer A, Nuessle D, Fend F, Brucker S, Taran FA, Kommoss S, Rothmund R.
    A prospective randomized experimental study to investigate the peritoneal adhesion formation after waterjet injection and argon plasma coagulation (HybridAPC) in a rat model,Arch Gynecol Obstet 2018 , PMID: 29362925.
  • Mischinger J, Kaufmann S, Russo GI, Harland N, Rausch S, Amend B, Scharpf M, Loewe L, Todenhoefer T, Notohamiprodjo M, Nikolaou K, Stenzl A, Bedke J, Kruck S.
    Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy,BJU Int 2018 , PMID: 29211932.
  • Büttner F, Winter S, Rausch S, Hennenlotter J, Kruck S, Stenzl A, Scharpf M, Fend F, Agaimy A, Hartmann A, Bedke J, Schwab M, Schaeffeler E.
    Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma,BMC Med 2018 , PMID: 29973214.
  • da Costa IA, Hennenlotter J, Stühler V, Kühs U, Scharpf M, Todenhöfer T, Stenzl A, Bedke J.
    Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis,Urol Oncol 2018 , PMID: 30119993.
  • Reustle A, Fisel P, Renner O, Büttner F, Winter S, Rausch S, Kruck S, Nies AT, Hennenlotter J, Scharpf M, Fend F, Stenzl A, Bedke J, Schwab M, Schaeffeler E.
    Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma,Int J Cancer 2018 , PMID: 30070687.
  • Schaeffeler E, Büttner F, Reustle A, Klumpp V, Winter S, Rausch S, Fisel P, Hennenlotter J, Kruck S, Stenzl A, Wahrheit J, Sonntag D, Scharpf M, Fend F, Agaimy A, Hartmann A, Bedke J, Schwab M.
    Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin,Eur Urol Focus 2019 , PMID: 29452772.
  • Neumann E, Klaiber P, Freitag K, Schwab M, Schaeffeler E, Hennenlotter J, Fend F, Kruck S, Scharpf M, Stenzl A, Bedke J, Rausch S.
    Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation,J Cancer Res Clin Oncol 2019 , PMID: 31006846.
  • Kraemer B, Tsaousidis C, Kruck S, Schenk M, Scharpf M, Kommoss S, Brucker S, Nuessle D, Enderle MD, Biber U.
    Safety and effectiveness of a novel generator algorithm for bipolar vessel sealing: a randomised controlled chronic animal study,BMC Surg 2019 , PMID: 31690302.
  • Reustle A, Di Marco M, Meyerhoff C, Nelde A, Walz JS, Winter S, Kandabarau S, Büttner F, Haag M, Backert L, Kowalewski DJ, Rausch S, Hennenlotter J, Stühler V, Scharpf M, Fend F, Stenzl A, Rammensee HG, Bedke J, Stevanović S, Schwab M, Schaeffeler E.
    Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy,Genome Med 2020 , PMID: 32228647.
  • Unsoeld M, Lamprecht U, Traub F, Hermes B, Scharpf M, Potkrajcic V, Zips D, Paulsen F, Eckert F.
    MR Thermometry Data Correlate with Pathological Response for Soft Tissue Sarcoma of the Lower Extremity in a Single Center Analysis of Prospectively Registered Patients,Cancers (Basel) 2020 , PMID: 32295076.
  • Karl A, Buchner A, Tympner C, Kirchner T, Ganswindt U, Belka C, Ganzer R, Burger M, Eder F, Hofstädter F, Schilling D, Sievert K, Stenzl A, Scharpf M, Fend F, Dorp FV, Rübben H, Schmid K, Porres-Knoblauch D, Heidenreich A, Hangarter B, Knuchel-Clarke R, Rogenhofer M, Wullich B, Hartmann A, Comploj E, Pycha A, Hanspeter E, Pehrke D, Sauter G, Graefen M, Stief C, Haese A.
    Correction to: The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence,World J Urol 2020 , PMID: 32076820.
  • Franko A, Berti L, Hennenlotter J, Rausch S, Scharpf MO, de Angelis MH, Stenzl A, Birkenfeld AL, Peter A, Lutz SZ, Häring HU, Heni M.
    Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes,J Pers Med 2020 , PMID: 32932589.
  • Kaufmann S, Kruck S, Gatidis S, Hepp T, Thaiss WM, Hennenlotter J, Schwenck J, Scharpf M, Nikolaou K, Stenzl A, Reischl G, la Fougère C, Bedke J.
    Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer,World J Urol 2020 , PMID: 31907632.
  • Franko A, Berti L, Guirguis A, Hennenlotter J, Wagner R, Scharpf MO, de Angelis MH, Wißmiller K, Lickert H, Stenzl A, Birkenfeld AL, Peter A, Häring HU, Lutz SZ, Heni M.
    Characterization of Hormone-Dependent Pathways in Six Human Prostate-Cancer Cell Lines: A Gene-Expression Study,Genes (Basel) 2020 , PMID: 33036464.
  • Franko A, Berti L, Hennenlotter J, Rausch S, Scharpf MO, Angelis MH, Stenzl A, Peter A, Birkenfeld AL, Lutz SZ, Häring HU, Heni M.
    Increased Expressions of Matrix Metalloproteinases (MMPs) in Prostate Cancer Tissues of Men with Type 2 Diabetes,Biomedicines 2020 , PMID: 33207809.
  • Maas M, Mayer L, Hennenlotter J, Stühler V, Walz S, Scharpf M, Kühs U, Neumann T, Stenzl A, Todenhöfer T.
    Prognostic impact of somatostatin receptor expression in advanced bladder cancer,Urol Oncol 2020 , PMID: 32773234.
  • Stühler V, Rausch S, Kroll K, Scharpf M, Stenzl A, Bedke J.
    The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma,World J Urol 2021 , PMID: 33638011.
  • Maas M, Mischinger J, Compérat E, Scharpf M, Fend F, Todenhöfer T, Stenzl A, Gakis G, Rausch S.
    Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?,World J Urol 2021 , PMID: 33881556.
  • Schmidt A, Armento A, Bussolati O, Chiu M, Ellerkamp V, Scharpf MO, Sander P, Schmid E, Warmann SW, Fuchs J.
    Hepatoblastoma: glutamine depletion hinders cell viability in the embryonal subtype but high GLUL expression is associated with better overall survival,J Cancer Res Clin Oncol 2021 , PMID: 34235580.
  • Potkrajcic V, Traub F, Hermes B, Scharpf M, Kolbenschlag J, Zips D, Paulsen F, Eckert F.
    Hypofractionated preoperative radiotherapy for high risk soft tissue sarcomas in a geriatric patient population,Radiol Oncol 2021 , PMID: 34821137.
  • Diesing K, Ribback S, Winter S, Gellert M, Oster AM, Stühler V, Gläser E, Adler F, Hartwig C, Scharpf M, Bedke J, Burchardt M, Schwab M, Lillig CH, Kroeger N.
    p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics,J Cancer Res Clin Oncol 2021 , PMID: 34499221.
  • Sauter-Meyerhoff C, Bohnert R, Mazzola P, Stühler V, Kandabarau S, Büttner FA, Winter S, Herrmann L, Rausch S, Hennenlotter J, Fend F, Scharpf M, Stenzl A, Ossowski S, Bedke J, Schwab M, Schaeffeler E.
    Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma,Cancers (Basel) 2021 , PMID: 34944839.
  • Harland N, Russo GI, Kaufmann S, Amend B, Rausch S, Erne E, Scharpf M, Nikolaou K, Stenzl A, Bedke J, Kruck S.
    Robotic Transrectal Computed Tomographic Ultrasound with Artificial Neural Network Analysis: First Validation and Comparison with MRI-Guided Biopsies and Radical Prostatectomy,Urol Int 2022 , PMID: 34404057.
  • Ribback S, Winter S, Klatte T, Schaeffeler E, Gellert M, Stühler V, Scharpf M, Bedke J, Burchardt M, Schwab M, Lillig CH, Kroeger N.
    Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC,World J Urol 2022 , PMID: 34859284.
  • Reustle A, Menig LS, Leuthold P, Hofmann U, Stühler V, Schmees C, Becker M, Haag M, Klumpp V, Winter S, Büttner FA, Rausch S, Hennenlotter J, Fend F, Scharpf M, Stenzl A, Bedke J, Schwab M, Schaeffeler E.
    Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma,Clin Transl Med 2022 , PMID: 35678045.
  • Büttner FA, Winter S, Stühler V, Rausch S, Hennenlotter J, Füssel S, Zastrow S, Meinhardt M, Toma M, Jerónimo C, Henrique R, Miranda-Gonçalves V, Kröger N, Ribback S, Hartmann A, Agaimy A, Stöhr C, Polifka I, Fend F, Scharpf M, Comperat E, Wasinger G, Moch H, Stenzl A, Gerlinger M, Bedke J, Schwab M, Schaeffeler E.
    A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy,Genome Med 2022 , PMID: 36109798.
  • Thaiss WM, Moser S, Hepp T, Kruck S, Rausch S, Scharpf M, Nikolaou K, Stenzl A, Bedke J, Kaufmann S.
    Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy,World J Urol 2022 , PMID: 35922717.
  • Keckstein JS, Keckstein S, Brunecker K, Neugebauer A, Nüssle D, Hoffmann S, Andress J, Neis F, Scharpf M, Enderle M, Rothmund R, Brucker SY, Jun MW, Kraemer B.
    Hybrid argon plasma coagulation (HybridAPC) versus sharp excision for the treatment of endometriosis: a prospective randomized clinical trial,Arch Gynecol Obstet 2023 , PMID: 35284956.
  • Maas M, Kurcz A, Hennenlotter J, Scharpf M, Fend F, Walz S, Stühler V, Todenhöfer T, Stenzl A, Bedke J, Rausch S.
    Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases,Int J Mol Sci 2023 , PMID: 36982302.